“通络三宝”闪耀中医药高质量发展大会：三款中药如何成为心血管健康守护者？

Core Viewpoint - The 21st century is witnessing a shift in life sciences research from Western to Eastern methodologies, aligning with Traditional Chinese Medicine (TCM) principles of holistic regulation and syndrome differentiation [1] Group 1: Research and Development Achievements - Professor Wu Yiling has developed the "Vascular Theory" through national research projects, leading to significant breakthroughs in the prevention and treatment of vascular diseases [1] - Three patented traditional Chinese medicines, known as "Tongluo Sanbao" (Tongxinluo Capsules, Shensongyangxin Capsules, and Qiliqiangxin Capsules), have been developed under this theory, demonstrating solid scientific evidence and clinical efficacy in treating cardiovascular diseases [1][5] Group 2: Clinical Research Outcomes - Tongxinluo Capsules have shown to stabilize vulnerable plaques and reduce the incidence of vascular events by 36%, with a 30% reduction in cardiovascular mortality risk and a 74% decrease in one-year recurrence risk, as published in JAMA [3] - Shensongyangxin Capsules have been proven to effectively treat ventricular premature beats and atrial fibrillation, outperforming conventional drugs in certain studies, and have shown a 40.4% reduction in atrial fibrillation recurrence risk post-ablation [4] - Qiliqiangxin Capsules have significantly reduced the risk of major composite events in chronic heart failure patients by 22%, with notable reductions in hospitalization and cardiovascular death risks [5] Group 3: Global Recognition and Impact - The success of "Tongluo Sanbao" in international markets has established a positive image for TCM and provided a model for its high-quality development [5][6] - The journey of "Tongluo Sanbao" reflects the integration of ancient wisdom with modern scientific research, showcasing TCM's potential to address global cardiovascular health challenges [6]